Lviv clinical bulletin 2023, 3(43)-4(44): 24-28

https://doi.org/10.25040/lkv2023.03-04.024

The effectiveness of magnesium compounds in the complex treatment of patients with arterial hypertension with concomitant chronic obstructive pulmonary disease

Posted onAuthorAdminЗалишити коментар / Leave a comment

T. Nazaruk

Odessa National Medical  University

Introduction. The combination of arterial hypertension and chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular complications. During exacerbations of COPD, almost every second patient has hypomagnesemia. In particular, intravenous magnesium (Mg) administration in stable patients with COPD has been shown to improve lung function and respiratory muscle strength. Numerous publications report positive impact of various magnesium compounds causing the decrease in blood pressure. The above justifies the expediency of further studying the effectiveness of magnesium compounds in hypertension with concomitant COPD.

The aim of the study. To determine the effectiveness of a fixed combination of magnesium and vitamin B6 in the complex treatment of patients with hypertension accompanied by COPD.

Materials and methods. 60 patients with stage II hypertension and concomitant COPD were subjected to clinical examination. The data of office and home blood pressure monitoring was supplemented with spirometry, electrocardiography, laboratory tests and results of EQ-5D, mMRC, CAT.

Results. Treatment with the additional fixed combination of magnesium and vitamin B6 (MgB6) in patients with hypertension accompanied by COPD reduced complaints and improved quality of life from (52,6 ± 3,4) points to (74,2 ± 3,8)  points (р < 0,001). In 25 (83,3 ± 6,8 %) patients treated with MgB6, it was possible to achieve the target blood pressure; while in the control group similar results were obtained only in (26,6 ± 8,1%) (р < 0,001). Aplication of a fixed MgB6 combination in patients with hypertension and COPD reduced the frequency of tachycardia from (23,3 ± 7,7)% to (3.3 ± 3.3)% (р < 0.02), and frequency of supraventricular extrasystole from (36,7 ± 8,8)% to (13.3 ± 6.2)% (р < 0.05). Improvement of repolarization processes was observed in (46,7 ± 9,1)% of patients who additionally received FC MgB6 and only in (16,7 ± 6,8)%, (p < 0,02) of the control group. Complex treatment with the addition of a fixed combination of MgB6 contributed to the improvement of spirometry parameters: FEV1 – from (55.9 ± 3.0) to (65.8 ± 4.4) (р < 0.05) and FEV1/FVC – from (62.3 ± 3.1) to (71,6 ± 3,4) (р < 0.05).

Conclusion. Complex treatment of patients with arterial hypertension and chronic obstructive pulmonary disease, in which a fixed combination of magnesium and vitamin B6 is added to the basic treatment, improved the clinical course of comorbidities, bioelectrical activity of the heart, reduced blood pressure, improved spirometry and quality of life.

References

  1. Antomonov MYu. Mathematical processing and analysis of medical and biological data. 2nd edition. Kyiv: Medinform, 2018. 579 р. (Ukrainian) 
  2. Voloshyna Vegetative dysfunctions after infections and possibilities of their correction in the general practice (review of the literature). Family medicine. European practices. 2019;1(81):52-61. https://doi.org/10.30841/2307-5112.1.2019.172198 (Ukrainian)
  3. Zharinov O, Ivaniv Y, Kuts VK. Functional diagnostics. The Fourth Wave; 2021. 784 р. (Ukrainian) 
  4. Bestall JC, Paul EA, Garrod R. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-586. https://doi.org/10.1136/thx.54.7.581
  5. Burtniak TZ, Potabasniy VA, Fesenko VI. Arterial hypertension with comorbid chronic obstructive pulmonary disease: relationship between tolerance to physical exercise and structural and functional state of the heart. Medicni Рerspektivi. 2019;24(4):59-68. https://doi.org/10.26641/2307-0404.2019.4.18926
  6. Do AmaralAF, Rodrigues-Junior AL, Filho JT et al. Effects of acute magnesium loading on pulmonary function of stable COPD patients. Med Sci Monit. 2008;14:CR524-529.
  7. EuroQol Research Foundation. EQ-5D User Guide. Version 3.0. https://euroqol.org/publications/user-guides.
  8. Feshchenko YuI, Gavrisyuk  VK,  Dzublik OYa, Mostovoy YM, Pertseva TO, Polyanska MO et al. Adapted clinical setting: chronic obstructive pulmonary disease (Part 1). Ukrainian Pulmonary Journal. 2019;2:5-17. https://doi.org/10.31215/2306-4927-2019-104-2-5-18
  9. Global Initiative for Chronic Obstructive Lung Diseases (GOLD) [Internet] Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2023]. Available from: https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf
  10. Global Initiative for Chronic Obstructive Lung Diseases (GOLD) [Internet] Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2018]. Available from: https://goldcopd.org/wpcontent/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
  11. Hogea SP, Tudorache E, Fildan AP, Fira-Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J. 2020;14(3):183-197. https://doi.org/10.1111/crj.13129
  12. Jones P, Harding G, Berry P. Development and first validation of the COPD Assessment Test. Eur Resp J. 2009;34(3):648-654. https://doi.org/10.1183/09031936.00102509
  13. Makwana S, Patel A, Sonagara M. Correlation between serum magnesium level and acute exacerbation in patients with Chronic Obstructive Pulmonary Disease (COPD). Cureus. 2022;14(6):e26229. https://doi.org/10.7759/cureus.26229
  14. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;1;41(12):1874-2071.
  15. Mathew AA, Panonnummal R. ‘Magnesium’-the master cation – as a drug-possibilities and evidences. Biometals. 2021;34(5):955-986. https://doi.org/10.1007/s10534-021-00328-7
  16. Ni H, Aye SZ, Naing C. Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2022;5(5):CD013506. https://doi.org/10.1002/14651858.CD013506.pub2
  17. Patni N, Fatima M, Lamis A, Siddiqui SW, Ashok T, Muhammad A et al. Magnesium аnd Hypertension: Decoding Novel Anti-hypertensives. Cureus. 2022;14(6):e25839. https://doi.org/10.7759/cureus.25839